BERKELEY, Calif., Dec. 11, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (NasdaqGM:XOMA - News), a leader in the discovery and development of antibody therapeutics, announced today the addition of John Varian to its Board of Directors. Varian currently serves as the Chief Operating Officer and Chief Financial Officer of Aryx Therapeutics, a biopharmaceutical company focused on the development of drugs designed to eliminate safety issues with well-established, commercially successful drugs.
